Pharmaceutical formulations

Abstract

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

1 .- 19 . (canceled) 
     
     
         20 . A pharmaceutical formulation comprising:
 a) a pharmaceutically acceptable excipient which is alcohol;   b) a compound which penetrates the nail plate and travels through the nail plate to a nail bed underlying said nail plate;   c) an emollient which is a cyclic polydimethylsiloxane containing from about 3 to about 9 silicon atoms; and   having an efficacy coefficient against having an efficacy coefficient against  Trichophyton rubrum  or  Trichophyton mentagrophytes  above 10;   wherein the compound is present in said pharmaceutical formulation in a concentration of from about 0.5% to about 15%; and   wherein said pharmaceutical formulation is for ungual administration to a human suffering from onychomycosis mediated at least in part by said  Trichophyton rubrum  or  Trichophyton mentagrophytes.      
     
     
         21 . The formulation of  claim 20 , wherein the compound is present in said pharmaceutical formulation in a concentration of from about 1% to about 10%. 
     
     
         22 . The formulation of  claim 20 , wherein the cyclic polydimethylsiloxane is cyclomethicone. 
     
     
         23 . The formulation of  claim 20 , further comprising an emollient which is diisopropyl adipate. 
     
     
         24 . The formulation of  claim 20 , wherein the emollient is present in an amount of from about 10% to about 50%. 
     
     
         25 . The formulation of  claim 20 , wherein said pharmaceutically acceptable excipient is propanol or isopropanol. 
     
     
         26 . The formulation of  claim 20 , wherein said pharmaceutically acceptable excipient is ethanol. 
     
     
         27 . The formulation of  claim 20 , further comprising an antioxidant. 
     
     
         28 . The formulation of  claim 27 , wherein said antioxidant is vitamin E. 
     
     
         29 . The formulation of  claim 20 , wherein said efficacy coefficient is of between about 10 and about 1000.